Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvement in fatigue in patients with psoriatic arthritis: Pooled results from 3 phase III, randomized, controlled trials - 11/08/17
Arthur Kavanaugh, MD, University of California, San Diego, School of Medicine; Dafna D. Gladman, MD, Toronto Western Research Institute; Christopher J. Edwards, MD, University Hospital Southampton; Airi Poder, MD, Clinical Research Centre Ltd; Frédéric Lioté, MD, University Paris Diderot; Paul Bird, PhD, University of New South Wales; Dianne Nguyen, MD, Celgene Corporation; Lichen Teng, PhD, Celgene Corporation; Philip J. Mease, MD, Swedish Medical Center and University of Washington School of Medicine
Le texte complet de cet article est disponible en PDF. Commercial support: 100% is sponsored by Celgene Corporation. |
Vol 76 - N° 6S1
P. AB47 - juin 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?